Hospital of Francisco Marroquin University, Guatemala City, Guatemala.
Int J Gynaecol Obstet. 2013 Jan;120(1):65-9. doi: 10.1016/j.ijgo.2012.07.023. Epub 2012 Oct 14.
To confirm the results of an earlier study assessing the safety and efficacy of a laparoscopic radiofrequency volumetric thermal ablation (RFVTA) system among women with symptomatic myomas.
In a prospective study at the Hospital of Francisco Marroquin University, Guatemala City, consecutive premenopausal women with symptomatic myomas seeking uterine-sparing treatment were enrolled between August 2008 and July 2011. The women were treated by RFVTA. Uterine fibroid symptom and health-related quality-of-life (UFS-QOL) questionnaires were completed at 0, 3, 6, and 12 months.
Among 114 women screened, 36 were enrolled (ages 33-51 years), and 35 were followed for 12 months. Symptom severity scores reduced significantly (P<0.05): baseline (63.3), 3 months (23.1), 6 months (15.4), 12 months (9.6). Health-related quality-of-life scores improved significantly (P<0.05): baseline (37.3), 3 months (79.9), 6 months (85.1), 12 months (87.7). The mean ± SD difference in uterine volume from baseline (215.2 ± 117.9 cm(3)) to 12 months (167.0 ± 120.8 cm(3)) was 48.2 cm(3) (95% CI: -22.8 to 119.2; P=0.192). Nine adverse events among 8 individuals were minor and unrelated to the procedure.
RFVTA of fibroids resulted in significantly improved symptom severity and quality-of-life scores and provides an outpatient uterine-sparing option for treatment of myomas.
验证一项早期研究的结果，该研究评估了腹腔镜射频热容积消融（RFVTA）系统治疗有症状子宫肌瘤女性的安全性和有效性。
在危地马拉城弗朗西斯科·马罗昆大学医院进行的前瞻性研究中，连续纳入了 2008 年 8 月至 2011 年 7 月期间因有症状子宫肌瘤寻求保留子宫治疗的绝经前妇女。对这些女性采用 RFVTA 进行治疗。在 0、3、6 和 12 个月时完成子宫肌瘤症状和健康相关生活质量（UFS-QOL）问卷。
在筛选的 114 名女性中，有 36 名（年龄 33-51 岁）被纳入研究，其中 35 名女性随访 12 个月。症状严重程度评分显著降低（P<0.05）：基线时（63.3）、3 个月时（23.1）、6 个月时（15.4）、12 个月时（9.6）。健康相关生活质量评分显著改善（P<0.05）：基线时（37.3）、3 个月时（79.9）、6 个月时（85.1）、12 个月时（87.7）。从基线（215.2 ± 117.9 cm³）到 12 个月时（167.0 ± 120.8 cm³）子宫体积的平均差异为 48.2 cm³（95%CI：-22.8 至 119.2；P=0.192）。8 名女性中的 9 起不良事件为轻微且与手术无关。
子宫肌瘤的 RFVTA 显著改善了症状严重程度和生活质量评分，并为子宫肌瘤的治疗提供了一种门诊保留子宫的选择。
